BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Veloxis Pharmaceuticals A/S (VELO) to Present at the Cowen and Company 32nd Annual Health Care Conference


2/29/2012 11:40:37 AM

HORSHOLM, Denmark, Feb. 29, 2012 /PRNewswire/ -- Edward Koval, senior vice president, business development, of Veloxis Pharmaceuticals A/S, will present at the Cowen and Company 32nd Annual Health Care Conference at 2:10 p.m. EST, Monday, March 5, at the Boston Marriott Copley Place in Boston. Mr. Koval will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro, Veloxis' candidate to prevent organ transplant rejection.

About Veloxis Pharmaceuticals A/S

Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability -- at low-scale up costs -- not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development.

For further information, please visit www.veloxis.com.

For U.S. investor and media contacts:

John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S
(732) 321-3208
jdw@veloxis.com

SOURCE Veloxis Pharmaceuticals A/S



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES